Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab
International Ophthalmology · 2023
DOI: 10.1007/s10792-023-02870-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Ophthalmology, 2023. Verfasst von Keisuke Hoshi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan. Hauptthemen laut MEDLINE: Uveitis, Macula Lutea, Wet Macular Degeneration. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: JST grants from JSPS KAKENHI Grants-in-Aid, JST grants.
Abstract (Originalsprache)
PURPOSE: To investigate baseline characteristics associated with the incidence of intraocular inflammation (IOI) after the intravitreal injection of brolucizumab (IVBr) for the treatment of neovascular age-related macular degeneration (nAMD). METHODS: This retrospective study included 66 eyes of 62 consecutive patients with nAMD who received IVBr (18 eyes were treatment naïve and 48 eyes had switched from other anti-vascular endothelial growth factor [VEGF] therapy). Baseline clinical characteristics were compared in non-IOI and IOI groups. RESULTS: Although a dry macula was achieved at a high rate even 6 months after IVBr, IOI occurred in 8 of 66 eyes (12.1%; all had switched therapy) during the study period. Baseline characteristics including age, sex, nAMD type, lens status, visual acuity, central macular thickness, and a history of diabetes did not differ between the groups. The number of previous anti-VEGF injections before IVBr was greater in the IOI group (P = 0.004), and the ratio of patients with a laser flare-cell photometry (LFCP) value over 15 photon count per millisecond (pc/ms) was higher in the IOI group (P = 0.017). Multivariate logistic regression analysis showed that a greater number of previous anti-VEGF injections (odds ratio [OR]: 1.12, P = 0.006; area under the curve: 0.82, cut-off score: 14.0) and an LFCP value over 15 pc/ms (OR: 81.6, P = 0.031) were significantly associated with the incidence of IOI after IVBr. CONCLUSION: A number of previous anti-VEGF injections greater than 14 and an LFCP value more than 15 pc/ms might be useful predictors of the incidence of IOI after IVBr in eyes with nAMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan.
- Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan. kunikata@oph.med.tohoku.ac.jp.
- Department of Retinal Disease Control, Tohoku University Graduate School of Medicine, Sendai, Japan. kunikata@oph.med.tohoku.ac.jp.
- Division of Clinical Cell Therapy Center for Advanced Medical Research and Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Retinal Disease Control, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Ophthalmic Imaging and Information Analytics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Förderung
- JST grants from JSPS KAKENHI Grants-in-Aid
- JST grants
Zitieren
APA
Hoshi, K., Kunikata, H., Aizawa, N., Yasuda, M., Okabe, T., Takizawa, H., Abe, T., & Nakazawa, T. (2023). Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab. International Ophthalmology. https://doi.org/10.1007/s10792-023-02870-4
Vancouver
Hoshi K, Kunikata H, Aizawa N, Yasuda M, Okabe T, Takizawa H, et al. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab. International Ophthalmology. 2023. doi:10.1007/s10792-023-02870-4
BibTeX
@article{Hoshi2023,
author = {Hoshi, Keisuke and Kunikata, Hiroshi and Aizawa, Naoko and Yasuda, Masayuki and Okabe, Tatsu and Takizawa, Hiroki and Abe, Toshiaki and Nakazawa, Toru},
title = {Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab},
journal = {International Ophthalmology},
year = {2023},
doi = {10.1007/s10792-023-02870-4}
}
EUVIMED